Business context and reporting period
Entity/period note: The filing is Ziopharm Oncology, Inc.’s Form 10-K for the fiscal year ended December 31, 2019—not an Alaunos Therapeutics filing. It also provides unaudited quarterly figures, including Q4 2019.
Ziopharm was a clinical-stage immuno-oncology company developing Sleeping Beauty cell therapies, including TCR and CAR-T programs, and a controlled IL-12 platform. It had no approved products and no significant product revenue.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Collaboration revenue | $0 | $146,000 |
| Research and development expense | $38.3 million | $34.1 million |
| General and administrative expense | $19.5 million | $19.9 million |
| Operating loss | $57.9 million | $53.9 million |
| Net loss | $117.8 million | $53.1 million |
| Net loss per share | $0.70 | Net income per share of $0.96 |
| Cash used in operating activities | $40.9 million | $49.5 million |
2019 net loss included a $60.8 million non-cash warrant inducement expense. Cash and cash equivalents were $79.7 million at year-end; working capital was $93.0 million. Total liabilities were $14.1 million, including lease liabilities; the filing does not identify material borrowings. Operating cash outflow improved year over year, while R&D spending rose 12%. Profit margins are not meaningful because the company had no 2019 revenue.
After year-end, the company raised approximately $98 million net through a public offering and at-the-market sales. Management expected available resources, including these proceeds, to fund operations into mid-2022; it had no committed additional capital sources. Shares outstanding increased from 181.8 million at year-end to approximately 213.0 million as of February 14, 2020.
Material changes and operating developments
- Net loss increased substantially, principally because of the non-cash warrant charge; 2018 common-stockholder income was also lifted by a $207.4 million related-party settlement credit, so reported earnings are not directly comparable.
- R&D expense increased by $4.2 million, reflecting T-cell costs, hiring, Gorilla IL-12 manufacturing and trial costs, and Houston facility work.
- Operating cash use declined from $49.5 million to $40.9 million. Financing provided $59.2 million in 2019, mainly from warrant exercises and ATM sales.
- The NCI-led Phase 2 personalized TCR trial began in October 2019; patient enrollment was expected in the first half of 2020. A Phase 2 IL-12/Libtayo trial was enrolling, and the IL-12/Opdivo Phase 1 trial had completed dosing.
- The company entered a TCR research and development agreement with MD Anderson and issued a warrant for 3.33 million shares, subject to clinical milestones. Its Eden BioCell joint venture with TriArm was established for CAR-T development in Greater China.
Outlook, risks and unusual items
- Management expected continuing losses and substantial development spending. Forecasted runway is an estimate subject to clinical, spending and financing uncertainties.
- Ziopharm reported interim clinical signals, including survival observations in small glioblastoma patient groups; these are preliminary and do not establish efficacy. The filing cautions that interim results may not predict final outcomes.
- A previously planned pivotal IL-12 glioblastoma trial remained paused while the company addressed chemistry, manufacturing and controls requirements. Further clinical progress depends on regulatory acceptance and successful manufacturing.
- Material risks include the early-stage nature of its programs, trial failure or delay, safety events, dependence on collaborators and licensed intellectual property, manufacturing and supply constraints, competition, and the need for future financing and potential shareholder dilution.
- Management and the auditor reported a material weakness in internal controls over monitoring and recording third-party clinical-trial costs. The auditor gave an adverse opinion on internal control, while issuing an unqualified opinion on the financial statements; remediation was underway.
- No material legal proceeding was identified as of December 31, 2019. The filing reported $11.9 million of specified contractual obligations, including leases, the NCI CRADA and license fees, apart from contingent milestones and royalties.
Important facts for investors to verify
- Confirm the issuer identity: this is Ziopharm Oncology, Inc. (ticker ZIOP), whereas the request metadata names Alaunos Therapeutics, Inc.
- Review the full financial statements and notes for the warrant inducement accounting, cash-flow reconciliation, lease liabilities and contractual commitments.
- Check subsequent financing proceeds, resulting share count and potential dilution from warrants, options and the MD Anderson warrant.
- Track clinical-trial enrollment, mature efficacy and safety data, and resolution of the IL-12 program’s manufacturing requirements.
- Assess whether the clinical-trial-cost control weakness has been remediated and whether management’s mid-2022 cash runway assumptions remain supportable.